The story of a forgotten medicine, and the people carrying it forward.
RN, BSN, MS Co-Founder
Pamela Holloway, RN, BSN, MS, is a regenerative health strategist with more than thirty years of experience spanning clinical nursing, U.S. Army leadership, international health systems, and regenerative agriculture. She served as Deputy Executive Director of the U.S. Army Well-Being Program, helped her husband build a 1,200-acre regenerative farm recognized globally, and in 2020 founded Health Recovery Ministry and Radical Resilience Health, whose volunteers have served more than 7,000 people. She co-founded OGPro to bridge scientific research and clinical practice — bringing ozonated glycerin out of the archives and into the hands of the veterinarians, physicians, and stewards using it today. Pamela is the author of OGPro Notes, a practitioner guide synthesizing research, clinical experience, and emerging standards.
DVM, CVA, FAAO Clinical Director, Co-Founder
Dr. Jim Bridge, DVM, CVA, FAAO, is a UC Davis–trained veterinarian with nearly four decades of clinical experience in regenerative, integrative, and ozone-based medicine. A Fellow of the American Academy of Ozonotherapy and an advisory board member of the American Academy of Ozone Therapy, he has played a central role in the modern clinical application of ozonated glycerin — integrating Charles Marchand's 19th-century research with contemporary veterinary practice, and treating hundreds of canine and feline patients with OG-based protocols. For 32 years he owned and operated Dana Capistrano Animal Clinic in Southern California before relocating to Southern Oregon, where he continues to treat complex and chronic cases and train practitioners in regenerative therapies. As Clinical Director of OGPro, Dr. Bridge oversees all clinical recommendations for safety and efficacy.
There are medicines that were once known, and then forgotten. Glycozone is one of them.
What he made was, by the standards of its day, remarkable — useful for wounds, for pain, for the infections that shadowed every operating room.
He called it Glycozone. Writing to the medical profession over the next two decades, he issued eighteen editions of a physician's manual describing its uses. The Treasury Department issued his company its own proprietary stamp — a distinction reserved for the era's leading pharmaceutical houses. Endorsing the preparations in print, Dr. E.R. Squibb of Brooklyn — founder of the pharmaceutical house that still bears his name — put his name to them. Rush Medical College used them. The Academy of Medicine heard papers on their use. The leading medical journals of the age carried them. This was not fringe medicine. It was medicine.
Gradually, over the years, the work was set aside. Not disproven; simply displaced. Newer remedies arrived, more easily made and more loudly sold, and the century moved past it. For almost a hundred years, Glycozone sat in archives while the people who might have been helped by it lived without its help.
In 2018, at an ozone-therapy conference in Las Vegas, a Japanese researcher stood at the podium and described what he believed was a new discovery — a stable, slow-releasing form of ozone held in glycerin. He did not know — no one in the room did — that the substance had been made before. In the audience, a veterinarian with thirty years of practice sat still longer than the rest of the room. His name was Dr. Jim Bridge. He had been looking for something like this for years without knowing what to call it, and what he saw described from the stage looked like the answer.
He went home and began to read. What he found was not a new compound but an old one — Charles Marchand's Glycozone, lost for nearly a century, arrived at again in a Japanese laboratory that had no idea it was retracing old ground. The history had been there all along, waiting in the archives for someone to go looking. Bridge sourced materials, began treating cases, and within months was seeing responses in cases for which he had few other tools.
He was not the only one who had been looking. When the pandemic came in 2020, Pamela Holloway — a nurse, an Army health systems leader, a builder of regenerative communities — watched it as a systems failure: by asking which therapies worked, and why they were not reaching people. The published research on ozone was already clear; it inactivated the pathogen on contact. Existing only as an unstable gas, however, it was difficult to deliver and impossible to place in the hands of an ordinary household. The tool existed, and the tool could not travel.
stable, portable, shelf-ready, slow-releasing over weeks instead of minutes — and she recognized what he was carrying.
Here was the missing form. Here was a medicine that could sit on a shelf, like aspirin, and be reached for when it was needed. Between his clinic and her sense of what medicine should be, a platform could exist. They built it together, and called it OGPro.
Because the work was almost lost once — and nearly passed by a second time, surviving only because a veterinarian in the back of a conference hall went home and thought to look for its history — OGPro exists to make sure it is not lost again. It is the place where the work of ozonated glycerin is being carried forward — the protocols, the training, the research, and the community of veterinarians, physicians, and stewards using it today. Whether you are treating patients, caring for pets, or learning to use OG at home, OGPro is where the work is being gathered, governed, and carried forward.
We believe ozonated glycerin belongs where it was before — in the hands of the people doing the quiet, ordinary work of easing suffering. In the clinic. In the barn. In the kitchen, beside the kettle and the first-aid tin. Wherever a body is hurting and someone is trying to help it. It was part of that work once. It can be again.
The work ahead is plain. Build the protocols. Train the practitioners. Gather the cases. Hold the community together through the next turn of the century — so that a hundred years from now, no one has to find Glycozone a third time. The work will already be here, in hands that have made it theirs.